Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Picard, O."" wg kryterium: Autor


Wyświetlanie 1-3 z 3
Tytuł:
Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
Autorzy:
Ben-Horin S; Department of Gastroenterology, Sackler School of Medicine, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Tel Aviv, Israel.; First Affiliated Hospital of Sun-Yatsen University, Guangzhou, China.
Ungar B; Department of Gastroenterology, Sackler School of Medicine, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Tel Aviv, Israel.
Kopylov U; Department of Gastroenterology, Sackler School of Medicine, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Tel Aviv, Israel.
Lahat A; Department of Gastroenterology, Sackler School of Medicine, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Tel Aviv, Israel.
Yavzori M; Department of Gastroenterology, Sackler School of Medicine, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Tel Aviv, Israel.
Fudim E; Department of Gastroenterology, Sackler School of Medicine, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Tel Aviv, Israel.
Picard O; Department of Gastroenterology, Sackler School of Medicine, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Tel Aviv, Israel.
Peled Y; Cardiology Department, Sheba Medical Center & Tel-Aviv University, Israel.
Eliakim R; Department of Gastroenterology, Sackler School of Medicine, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Tel Aviv, Israel.
Del Tedesco E; Department of Gastroenterology, University Hospital of Saint Etienne, Saint Etienne, France.
Paul S; Department of Gastroenterology, University Hospital of Saint Etienne, Saint Etienne, France.
Roblin X; Department of Gastroenterology, University Hospital of Saint Etienne, Saint Etienne, France.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2018 Apr; Vol. 47 (8), pp. 1117-1125. Date of Electronic Publication: 2018 Feb 15.
Typ publikacji:
Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Adalimumab/*administration & dosage
Antibodies, Monoclonal, Humanized/*administration & dosage
Gastrointestinal Agents/*administration & dosage
Inflammatory Bowel Diseases/*drug therapy
Infliximab/*administration & dosage
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
Adalimumab/adverse effects ; Adalimumab/pharmacokinetics ; Adult ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/pharmacokinetics ; Case-Control Studies ; Female ; Gastrointestinal Agents/adverse effects ; Gastrointestinal Agents/pharmacokinetics ; Humans ; Inflammatory Bowel Diseases/metabolism ; Infliximab/adverse effects ; Infliximab/pharmacokinetics ; Male ; Middle Aged
Czasopismo naukowe
Tytuł:
Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.
Autorzy:
Ungar B; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Kopylov U; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Engel T; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Yavzori M; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Fudim E; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Picard O; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Lang A; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Williet N; Service de Gastrologie-Entérologie-Hépatologie, CHU de Saint-Etienne, Saint-Etienne, France.
Paul S; Service de Gastrologie-Entérologie-Hépatologie, CHU de Saint-Etienne, Saint-Etienne, France.
Chowers Y; Rambam Health Care Campus, Bruce & Ruth Rappaport School of Medicine, Technion Institute of Technology, Haifa, Israel.
Bar-Gil Shitrit A; Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
Eliakim R; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Ben-Horin S; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Roblin X; Service de Gastrologie-Entérologie-Hépatologie, CHU de Saint-Etienne, Saint-Etienne, France.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2017 Jan; Vol. 45 (2), pp. 276-282. Date of Electronic Publication: 2016 Nov 16.
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
Adalimumab/*therapeutic use
Anti-Inflammatory Agents/*therapeutic use
Antibody Formation/*drug effects
Colitis, Ulcerative/*drug therapy
Crohn Disease/*drug therapy
Immunologic Factors/*therapeutic use
Adalimumab/adverse effects ; Adult ; Anti-Inflammatory Agents/adverse effects ; Antibodies/blood ; Azathioprine/therapeutic use ; Colitis, Ulcerative/blood ; Crohn Disease/blood ; Female ; Humans ; Male ; Mercaptopurine/therapeutic use ; Methotrexate/therapeutic use ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł:
The decline of anti-drug antibody titres after discontinuation of anti- TNFs: implications for predicting re-induction outcome in IBD.
Autorzy:
Ben‐Horin, S.
Mazor, Y.
Yanai, H.
Ron, Y.
Kopylov, U.
Yavzori, M.
Picard, O.
Fudim, E.
Maor, Y.
Lahat, A.
Coscas, D.
Eliakim, R.
Dotan, I.
Chowers, Y.
Pokaż więcej
Temat:
MONOCLONAL antibodies
INFLIXIMAB
ADALIMUMAB
INFLAMMATORY bowel diseases
TUMOR necrosis factors
PATIENTS
Źródło:
Alimentary Pharmacology & Therapeutics; Mar2012, Vol. 35 Issue 6, p714-722, 9p, 3 Charts, 3 Graphs
Czasopismo naukowe
    Wyświetlanie 1-3 z 3

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies